Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 4/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132967 | 0.94 | RAB9A (0.44) | RXRARXRBDHODHKMORORC | |
| SCHEMBL133749 | 0.88 | KMO (0.53) | DHODHKMOGRM5L3MBTL1 | |
| SCHEMBL12551824 | 0.88 | KMO (0.53) | DHODHKMOGRM5L3MBTL1 | |
| SCHEMBL133475 | 0.86 | EGFR (0.46) | DHODHKMOMAPTL3MBTL1 | |
| SCHEMBL12551833 | 0.83 | KMO (0.53) | RXRARXRBDHODHKMOMAPT | |
| SCHEMBL12551667 | 0.83 | KMO (0.53) | RXRARXRBDHODHKMOMAPT | |
| SCHEMBL10039117 | 0.83 | KMO (0.53) | RXRARXRBDHODHKMOMAPT | |
| SCHEMBL4546948 | 0.83 | L3MBTL1 (0.55) | DHODHKMOMAPTRAB9AL3MBTL1 | |
| SCHEMBL4546942 | 0.83 | L3MBTL1 (0.55) | DHODHMAPTRAB9AL3MBTL1 | |
| SCHEMBL10128397 | 0.83 | L3MBTL1 (0.55) | DHODHMAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136343-B2 | Binuclear metal complexes for use as emitters in organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20190292210-A1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292210-A1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | AP2M1, MCU, AP3M1 | RXRA 2696/4885RXRB 2827/4885DHODH 3665/4885 |
| US-11136343-B2 | Binuclear metal complexes for use as emitters in organic electroluminescent devices | AP2M1, MCU, AP3M1 | RXRA 2696/4885RXRB 2827/4885DHODH 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.